Stock Analysis
NGL Fine-Chem Third Quarter 2025 Earnings: EPS: ₹2.07 (vs ₹16.24 in 3Q 2024)
NGL Fine-Chem (NSE:NGLFINE) Third Quarter 2025 Results
Key Financial Results
- Revenue: ₹889.7m (up 1.2% from 3Q 2024).
- Net income: ₹12.8m (down 87% from 3Q 2024).
- Profit margin: 1.4% (down from 11% in 3Q 2024).
- EPS: ₹2.07 (down from ₹16.24 in 3Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NGL Fine-Chem shares are up 17% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 1 warning sign for NGL Fine-Chem that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if NGL Fine-Chem might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:NGLFINE
NGL Fine-Chem
Manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide.